Pay more attention to and standardize drug therapy for vascular diseases        WU Qing-hua. Department of Vascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing100029, China
Abstract    Drug therapy plays an important role in the treatment for vascular diseases just as the same as surgical and endovascular treatment. Vascular surgeons are found to treat atherosclerotic risk factors less diligently in patients with peripheral arterial disease than in patients with coronary arterial diseases or cerebral arterial diseases. In addition to therapies directed at treatment of limb symptoms, vascular surgeons should treat risk factors because patients are at very high risk for future cardiovascular events and mortality including antiplatelet therapy, lipid-lowering therapy, control of diabetic mellitus and high blood pressure. Study demonstrated antiplatelet treatment is effective in preventing thrombosis of stents or grafts. Most of trials showed duration of anticoagulation for venous thromboembolism should be at least three months. Insufficent anticoagulation time may result in higher incidence of reoccurrence. Because of a paucity of trials, the standard of drug therapy is often controversial in China. It should emphasize on clinical trials to establish guideline for drug therapy in China. Vascular surgeons often neglect comprehensive drug therapy. Paying more attention to standardization of drug therapy will improve the results of treatment.